Neuren Pharmaceuticals

DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks

AnalystConsensusTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

23 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

AU$24.87

34.2% undervalued

15 Aug

AU$16.35

5.0%

-8.0%

Author's Valuation

AU$24.9

34.2% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Increased 1.74%

AnalystConsensusTarget Fair Value

AU$24.9

34.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-6.25%

Pharma revenue growth rate

1.05%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$70.26m

Earnings '28

52.55x

PE Ratio '28

AU$3.69b

Market Cap '28

AU$3.69b

Market Cap '28

124.63m

No. shares '28

AU$29.62

Share Price '28

AU$29.62 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$24.54

Fair Value '25

DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks

Shared on01 May 25Fair value Increased 1.74%

Shared on01 May 25
Fair value Increased 1.74%